Literature DB >> 33301465

Urinary tract infection in cancer patients and antimicrobial susceptibility of isolates in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.

Wondewosen Tseagye Sime1, Habtamu Biazin2, Tamrat Abebe Zeleke2, Zelalem Desalegn2.   

Abstract

BACKGROUND: Urinary tract infections are the most common causes of morbidity and mortality in patients with cancer. The emergence of multiple-drug-resistant (MDR) strains of gram-negative bacteria causing urinary tract infection has become a serious concern in cancer patients. Therefore, the present study aimed to determine the spectrum and antibiotic resistance pattern of bacterial isolates related to urinary tract infections among cancer patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. METHODS AND MATERIALS: Hospital based prospective cross-sectional study was conducted for three months from January to March 2018 in tertiary care hospital located in the capital city of the country. Gram-negative bacteria isolated from urine specimens from hospitalized patients with cancer were characterized using standard microbiological methods. Modified Kirby-Bauer disk diffusion technique was applied for antimicrobial susceptibility testing in accordance with CLSI 2019 criteria.
RESULTS: Of totally 292 urine samples tested, eighteen (6.3%) were culture positive cases, Escherichia coli (44.4%) was the highest proportion isolated uropathogen followed by Klebsiella pneumoniae (22.2%) and Citrobacter diversus (16.7%). The antibiotic susceptibility results showed meropenem and nitrofurantoin as the most effective antibiotics for E. coli, K. pneumoniae, and Citrobacter diversus isolates. The rate of multidrug resistant (MDR) isolates were 33.3% (6/18), and meropenem and nitrofurantoin were the most effective antibiotic against MDR isolates.
CONCLUSION: The study findings showed a significant distribution of MDR gram-negative bacteria which may increase the burden of urinary tract associated infections in cancer patients. Carbapenem (meropenem) can be considered as effective agents to treat MDR cases in our region.

Entities:  

Year:  2020        PMID: 33301465      PMCID: PMC7728278          DOI: 10.1371/journal.pone.0243474

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Cancer is a significant cause of death worldwide, and more than half of them occur in developing countries. The most common causes of cancer death are lung, liver, colorectal, stomach, breast cancer, cervical cancer, and leukemia [1]. The new advances in treatment options increased survival rates of cancer patients in the past decades [2]. However, severe immunosuppression as an adverse consequence of these treatment strategies increases the risk of opportunistic infections. Infections are one of the most serious complications and the leading cause of morbidity and mortality in patients with cancer [3]. There are several risk factors for acquisition of infections such as neutropenia, stem cell transplantation, long-term catheterization, and the extensive use of medical devices such as stents, shunts and central venous catheters [3, 4]. One of the most common infection in cancer patients is urinary tract infections (UTIs) [3, 4]. A wide range of bacteria has been reported as a cause of urinary tract infections that among them, Enterobacteriaceae are the most prevalent [4]. The emergence of multiple-drug-resistant (MDR) strains of Gram-negative bacteria causing UTIs has become a serious concern, especially in cancer patients [5]. The incidence of infections caused by multi-drug resistant (MDR) bacteria has been increasing throughout the world [6, 7]. The number and MDR spectrum of microbial infections might increase by the administration of new, stronger immunosuppressive regimens [8]. In recent years, the majority of conducted studies in cancer patients have only focused on blood stream infections, and there is scarcity of information with regards to the overall prevalence of gram-negative bacteria related among cancer patients suspected with urinary tract infection in Ethiopia. Therefore, the present study aimed to determine the spectrum and antibiotic resistance pattern of gram-negative bacteria related urinary tract infections among cancer patients. This information can help clinicians to choose effective therapies and provide good epidemiological profiles to compare our situation with others.

Materials and methods

Study area, design, and period

The study was conducted at Tikur Anbessa specialized hospital from January up to March 2018. A prospective hospital based cross-sectional study design was employed.

Study population

All adult female cancer patients during the study period were considered as a study population.

Clinical and laboratory data

Clinical data

A structured questionnaire was used to collect clinical data and physicians collected the relevant clinical data.

Urine samples collection and processing

Early morning 5 ml mid-stream clean catch urine [MSU] specimens was collected using lick proof re-usable sterile plastic containers on the same day of enrolment. All the specimens were processed within an hour of collection.

Bacterial isolation

Using calibrated wire loop [0.001 ml] samples were inoculated in to Cysteine Lactose Electrolyte Deficient medium [CLED] agar. After overnight incubation at 37°C for 24–48hours colonies were counted to check significant growth. Colony counts yielding bacterial growth of 105/ml [A diagnosis of UTI was made when there are at least 105 colony forming unit (CFU)/ml] of urine was regarded as significant for bacteriuria. Colonies from CLED were sub cultured into MacConkey agar and blood agar plates [BAP] [Oxoid, LTD] and incubated at 37°C for 24–48 hours. Identification of bacteria were done using colony characteristics, gram reaction of the organisms and biochemical tests following standard bacteriological procedure [9, 10]. All laboratory procedures were conducted in Black Lion specialized hospital laboratory and the same senior laboratory technologist performed the tests in all the time to avoid professional biases. For contaminated specimens, culture was repeated.

Antimicrobial susceptibility testing (AST)

All identified pure bacterial isolates were subjected to in vitro susceptibility testing by Modified Kirby Bauer as previously described [11-13] for 12 antibiotics such as amoxicillin-clavulanic acid (Augmentin) (20μg), ampicillin (30μg), ciprofloxacin (5μg), Nitrofurantoin (300ug), Ceftazidime (10μg), gentamicin (10 μg), co-trimoxazole (Trimethoprim-Sulfamethoxazole) (25 μg), Meropenem (10μg), Cefepime (30μg), Piperacillin-Tazobactam (16μg), Chloramphenicol (30μg), and Ceftriaxone (10μg). A suspension of a pure colony from each confirmed culture isolate was prepared by using 0.85% sterile normal saline, and the suspension was adjusted at 0.5% MacFarland standard. The suspension was swabbed uniformly over entire surface of a sterile Muller Hinton Agar (MHA) plate. The antibiotics discs were placed on inoculated plate no closer than 15 mm from the edge and 24 mm from center of discs. The plates were then left at room temperature for 15 minutes for pre-diffusion and then incubated at 37°C. Diameter of the zone of inhibition around the disc was measured to the nearest millimeter using a metal caliper and the isolate was classified as sensitive, intermediate and resistant according to CLSI 2019 [12]. Isolates were considered as multi drug resistant (MDR) if bacterial isolates are non-susceptible to greater than or equal to three or more antimicrobial categories [14] Standard quality control ATCC strains with known minimum inhibitory concentration including Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were included in each run.

Data analysis

As a first step of data management, the collected data was checked for its completeness, unrecorded values and unlikely responses. Accordingly, data cleaning was done manually whenever such indications are encountered. The laboratory results were registered onto a well-designed laboratory registration log book.

Statistical analysis

Data from the questionnaire and laboratory registration book were entered to Epi info version 6 and then exported to SPSS version 25 for further analysis. Using the parameters in SPPS, descriptive statistics like frequency distribution and proportion were computed. The analyzed data were presented using appropriate table format based on the types of the variables. Logistic regression analysis was performed. The strength of association between dependent and independent variables were measured using Odd ratio [OR] and 95% CI. The current research established P-value < 0.05 as an indicator of statistical significance.

Ethical approval

The ethical clearance and approval was secured from College of Health Sciences research and ethics review committee. Following the clearance and approval, a supporting letter from the research directorate office was written to Tikur Anbessa specialized hospital to obtain permission letter. A written informed consent was obtained from all study participants involved in the study. The result of the research kept confidential. Confidentiality was maintained by numeric coding of samples and questionnaires. The objectives of the study and its benefits explained to the participants. Those identified positive for bacteriuria during the study period results were communicated to attending physicians and treated by appropriate drugs in line with the national guidelines for treatment.

Results

Sociodemographic characteristics

In this study, a total of 292 female cancer patients were enrolled. The mean age of study participants was 46.55±13.21 years, range 18–85 years. Most of the study participants were found in the age group of 38–45 which accounts 65 (22.3%), followed by age group 46–53 accounts 63 (21.6%). The majority of study subjects had no formal education 179 (61.3%), and 188 (64.4%) had housewife as their occupation (Table 1).
Table 1

Socio-demographic characteristics of study participants at TASH, Addis Ababa, Ethiopia.

CharacteristicsFrequencyPercentage
Age group18–2172.4
22–29206.8
30–375117.5
38–456522.3
46–536321.6
54–614716.1
62–69258.6
70–77113.8
78–8531.0
ResidenceUrban15252.1
Rural14047.9
ReligionOrthodox20168.8
Muslim5719.5
Protestant3110.6
Other31.0
Education statusIlliterate17961.3
Read and Write124.1
Elementary (1–8)4314.7
High School3712.7
Certificate72.4
Degree and Above144.8
OccupationHouse Wife18864.4
Government258.6
Private Employee175.8
Merchant41.4
Farmer3612.3
Student72.4
House Maid2.7
Commercial Sex worker1.3
No job103.4
Other2.7
Monthly income< = 50024082.2
501–1000227.5
1001–150062.1
>1500248.2
Total292100.0

Clinical characteristics of study participants

Out of 292 cancer patients, 40 (13.7%) had hematological malignancy and 252 (86.3%) wee solid organ malignancy patients respectively. Among solid malignancy, cervical cancer was the predominant proportion which accounts 107 (36.6%) followed by breast cancer 58 (19.9%). Majority of the solid cancer patients had clinical stage I which was 136 (46.6%), followed by clinical stage II which was 87(29.8) and most of them 244 (83.6%) has localized progression of cancers. Very few study participants had a history of smoking, family history of cancer and experience of cancer screening as shown in Table 2.
Table 2

Clinical characteristics of cancer patients at TASH, Addis Ababa, Ethiopia.

Clinical profilesFrequencyPercentage
Type of CancerHematological4013.7
Solid25286.3
SolidBreast5819.9
Pharyngeal124.1
Cervical10736.6
Colorectal175.8
Other9833.6
Stages of solid cancerGrade I13646.6
Grade II8729.8
Grade III4515.4
Grade IV248.2
Progression of cancerLocalized24483.6
Disseminated4816.4
History of hospitalizationYes11840.4
No17459.6
Duration of hospitalization< = 3mnt9076.3
>3mnt54.2
History of taking antibiotics in six last monthYes8830.1
No20469.9
History of catheterizationYes31.0
No28999.0
Family history of cancerYes31.0
No28999.0
Experience of cancer screeningYes31.0
No28999.0
Experience of smokingYes31.0
No28999.0
Living with other smokersYes196.5
No27393.5
History of surgical incisionYes9231.5
No20068.5
Total292100.0
One hundred eighteen (40.4%) of the study participants had a history of hospitalization. Of which 90 (72.3%) had less than three months of hospitalization. Ninety-two (31.5%) of the participants had history of surgical incision. None of the study participants was working experience in chemical industry or radiation. Eighty-eight (30.1%) of the study participants had a history of taking antibiotics in the last six months. None of the clinical features of the study participants were associated with the urinary tract infections.

Bacterial profiles and site of isolation

Of 292 cancer patients included in this study, 18 (.6.2%) were positive for bacterial culture. The isolates were E. coli 44.4% (8), K. pneumoniae 22.2% (4), Citrobacter diversus 16.7% (3), Providentia rettgeri 11.1% (2), and Enterobacter cloacae 5.6% (1). Polymicrobial growth was not detected in any of the clinical specimen (Table 3).
Table 3

Bacterial profiles among cancer patients at TASH, Addis Ababa, Ethiopia.

Bacterial profilesFrequencyPercentage
Bacterial growthPositive186.2
Negative27493.8
Bacterial isolatesE.coli844.4
Klebsiella pneumonia422.2
Citrobacter diversus316.7
Providentia rettgeri211.1
Enterobacter cloacae15.6

Antimicrobial resistance pattern and multidrug resistance (MDR)

In this study, high resistance rates were observed to Ampicillin 12 (66.7%), Augmentin 11(61.1%), and Ceftriaxone 10 (55.6%). On the other hand, a low resistance rate was detected for Meropenem 2(11.1%), Ciprofloxacin 3 (16.7%), Nitrofurantoin 2 (11.1%) and Piperacillin-Tazobactam 3(16.7%). E. coli isolates were resistant at least for one antibiotics tested. But, the antibiotic susceptibility results showed meropenem and nitrofurantoin as the most effective antibiotics for E.coli isolates. Gentamycin, meropenem, ciprofloxacin, and nitrofurantoin were the most effective antibiotics for K. pneumoniae isolates. However, 75% of K. pneumoniae isolates were resistant for Trimethoprim-Sulfamethoxazole and ampicillin. Fifty percent of the isolates of Providentia rettgeri were resistant for meropenem, chloramphenicol and Nitrofurantoin but completely resistant for Augmentin, Ampicillin, and Ceftriaxone. Citrobacter diversus isolates were completely resistant for Augmentin and 66.7% resistant for Ampicillin, Cefepime, and Ceftriaxone as shown in Table 4.
Table 4

Antimicrobial resistance pattern of isolates from cancer patients at TASH, Addis Ababa, Ethiopia.

Antimicrobial testedIsolates, n = 18 (%)Total
ClassesAntibioticsE. coli, n = 8K.pneumoniae, n = 4C.diversus, n = 3P.rettgeri, n = 2E.cloacae, n = 1n (%)
AminoglycosidesGM4 (50)01 (33.3)005(27.8)
SulfonamidesSXT5(62.5)3(75)1(33.3)009(50)
ChloramphenicolCHL3(37.5)2(50)1(33.3)1(50)07(38.9)
QuinolonesCIP2(25)01(33.3)003(16.7)
NitrofuransFM1(12.5)001(50)02(11.1)
Beta lactamAm4(50)3(75)2(66.7)2(100)1(100)12(66.7)
CAX5(62.5)1(25)2(66.7)2(100)010(55.6)
FEP5(62.5)1(25)2(66.7)1(50)09(50)
CAZ2(25)2(50)0004(22.2)
MEN1(12.5)001(50)02(11.1)
TZP2(25)1(25)0003(16.7)
AUG3(37.5)2(50)3(100)2(100)1(100)11(61.1)

Abbreviations: GM- Gentamycin, SXT-Trimethoprim-Sulfamethoxazole, CIP- Ciprofloxacin, TZP-Piperacillin-Tazobactam, CHL-Chloramphenicol, FM- Nitrofurantoin, CAX-Ceftriaxone, CAZ Ceftazidime, AM-Ampicillin, MEN- Meropenem, FEP- Cefepime, AUG- Augmentin.

Abbreviations: GM- Gentamycin, SXT-Trimethoprim-Sulfamethoxazole, CIP- Ciprofloxacin, TZP-Piperacillin-Tazobactam, CHL-Chloramphenicol, FM- Nitrofurantoin, CAX-Ceftriaxone, CAZ Ceftazidime, AM-Ampicillin, MEN- Meropenem, FEP- Cefepime, AUG- Augmentin. Multidrug resistances were detected in 33.3% of bacterial isolates, while one (12.5%) bacterial isolates were sensitive to all antibiotics tested. None of the isolated bacterial pathogens were resistant for all antibiotics classes tested. However, the result of MDR patterns compared within the species showed that 50% of E. coli isolates were MDR and 33.3% of Citrobacter diversus isolates were MDR, followed by Klebsiella pneumoniae (25%). All recovered isolates of Providentia rettgeri were resistant at least for two class of antibiotics as shown in Table 5.
Table 5

Multidrug resistance patters of bacterial isolates from cancer patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.

Bacterial isolatesAntibiogram pattern, n (%)
R0R1R2R3R4R5MDR
E.coli1(12.5)03(37.5)1(12.5)2(25)1(12.5)4(50)
Klebsiella pneumoniae003(75)1(25)001(25)
Citrobacter diversus02(66.6)0001(33.3)1(33.3)
Providentia rettgeri002(100)0000
Enterobacter cloacae01(100)00000
Total1(5.6)3(16.7)8(44.4)2(11.1)2(11.1)2(11.1)6(33.3)

Note: R0: sensitive for all class of antibiotics, R1: resistant for one class of antibiotics, R2: resistant for two class of antibiotics, R3: resistant for three class of antibiotics, R4: resistant for four class of antibiotics, R5: resistant for five class of antibiotics, MDR-multidrug resistance.

Note: R0: sensitive for all class of antibiotics, R1: resistant for one class of antibiotics, R2: resistant for two class of antibiotics, R3: resistant for three class of antibiotics, R4: resistant for four class of antibiotics, R5: resistant for five class of antibiotics, MDR-multidrug resistance.

Discussion

The management of urinary tract infections in patients with cancer is a priority of public health due to its rapid onset and high level of morbidity and mortality [14]. Due to diverse nature of urinary tract infections etiology and antibiotic resistance patterns in periodic intervals, routine surveillance is needed to prevent the occurrence and transmission of urinary tract infections pathogens [15-17]. In the present study, we analyzed the distribution and antibiotic resistance of bacterial pathogens isolated from urinary tract infection from cancer patients at Tikur Anbessa specialized hospital cancer center. In this study, the culture positivity rate was 18/292 (6.2%) among cancer patients. This finding was significantly lower with comparison with those that were previously reported in Gondar, Addis Ababa, and Egypt [14, 18, 19]. This variation could be study area difference since cancer patients relatively have close supervision and they get better treatment regimens. E. coli (44.4%) was the most common organism isolated in cancer patients with UTI. This finding was in agreement with the study conducted in Egypt (30%) and India (40%) [19, 20]. However, this finding was lower (60.6%) than the study documented in Iranian cancer patients [21] and higher than (21.2%) the study recorded in Gondar [14]. The second frequently isolated gram-negative bacteria were Klebsiella pneumonia (22.2%) which is in lined with the study documented by Ashour and El-Sharif [19]. The observed discrepancy could be explained as due to geographic variation, sample size, study population and source of infections. Intriguingly, we did not identify any gram positive bacteria and Pseudomonas aeruginosa from gram negative bacteria in our study participants even if these uropathogen were a commonly isolated as etiologic agent of UTI [21-23]. Many demographic factors and clinical features were analyzed as risk factors for bacteriuria in cancer patients in this study, however, no evidence was found to support the association between bacteriuria and demographic and clinical features of the cancer patients (P > 0.05). Correspondingly, in other studies [24-26] reported that neither of the factors and clinical features mentioned in our study had no effect on the occurrence of bacteriuria. In our study, the estimated rate of MDR isolates was 33.3%, while 12.5% of the isolates were sensitive to all antibiotics tested which is in lower than the study documented 46.5% respectively) in Gondar cancer patients (14) and (54.4%) in Egyptian cancer patients [19]. In our study, 50% of E. coli isolates were Multidrug resistance. This finding was in line with the study conducted in Gondar, Egypt and India [14, 19, 20]. In this study, the highest resistance was recorded in Augmentin (61.1%), Ampicillin (66.7%) and Ceftriaxone (55.6%). This finding is in line with the study documented in Addis Ababa, Augmentin (80%), and Ceftriaxone (73.3%) respectively [18]. Our results showed that Meropenem and nitrofurantoin as the most effective antibiotics toward E. coli isolates. This finding was in agreement with the study documented in Addis Ababa cancer patients. However, higher resistance proportion for Trimethoprim-Sulfamethoxazole was documented [18]. Whereas, Gentamycin, Meropenem, Ciprofloxacin, and Nitrofurantoin were the most effective antibiotics for K.pneumoniae isolates. This finding is in agreement with the study previously reported in Iranian cancer patients [18]. As a limitation of this study, though in immunocompromised patient like cancer patients, the fungal agents especially Candidia are the most common etiologic agent of UTI, we did not test for the fungal agents as the causative agent of UTI due to the constraint of laboratory consumables. In addition, we did not test extended beta lactamase producing bacterial isolates which are the main sources of drug resistances.

Conclusion

The overall burden of bacterial infections among cancer patients is considerably high. The most common bacterial isolates were E. coli and K. pneumoniae. This study finding showed that a significant distribution of MDR gram negative bacteria which may increase the burden of urinary tract associated infections in cancer patients.

Questionnaire used to gather risk factors associated with urinary tract infection in cancer patients.

(DOCX) Click here for additional data file.
  22 in total

Review 1.  Urinary tract infections: contemporary management.

Authors:  David D Rahn
Journal:  Urol Nurs       Date:  2008-10

Review 2.  The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions.

Authors:  M J Struelens
Journal:  BMJ       Date:  1998-09-05

3.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

4.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

Review 5.  Nosocomial infections in patients with cancer.

Authors:  Mini Kamboj; Kent A Sepkowitz
Journal:  Lancet Oncol       Date:  2009-06       Impact factor: 41.316

Review 6.  Epidemiology of urinary tract infections: incidence, morbidity, and economic costs.

Authors:  Betsy Foxman
Journal:  Am J Med       Date:  2002-07-08       Impact factor: 4.965

7.  Effect of Preoperative Bacteriuria and Pyuria on Intravesical Recurrence in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy.

Authors:  Hiroshi Fukushima; Masaki Kobayashi; Keizo Kawano; Shinji Morimoto
Journal:  In Vivo       Date:  2017 Nov-Dec       Impact factor: 2.155

8.  Epidemiological surveillance of bacterial nosocomial infections in the surgical intensive care unit.

Authors:  Amer Custovic; Jasmina Smajlovic; Sadeta Hadzic; Sead Ahmetagic; Nijaz Tihic; Haris Hadzagic
Journal:  Mater Sociomed       Date:  2014-02-20

9.  Bacterial profile, antibiotic resistance pattern and associated factors among cancer patients at University of Gondar Hospital, Northwest Ethiopia.

Authors:  Alelign Fentie; Yitayih Wondimeneh; Abera Balcha; Anteneh Amsalu; Birhanemeskel Tegene Adankie
Journal:  Infect Drug Resist       Date:  2018-11-08       Impact factor: 4.003

10.  Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients.

Authors:  Hossam M Ashour; Amany El-Sharif
Journal:  J Transl Med       Date:  2009-02-19       Impact factor: 5.531

View more
  2 in total

1.  Bacterial uropathogens and burden of antimicrobial resistance pattern in urine specimens referred to Ethiopian Public Health Institute.

Authors:  Tesfa Addis; Yonas Mekonnen; Zeleke Ayenew; Surafel Fentaw; Habtamu Biazin
Journal:  PLoS One       Date:  2021-11-12       Impact factor: 3.240

2.  Diagnostic value of different urine tests for urinary tract infection: a systematic review and meta-analysis.

Authors:  Rong Xie; Xinli Li; Guangquan Li; Rong Fu
Journal:  Transl Androl Urol       Date:  2022-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.